Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience

CONCLUSION: Although no statistically significant differences have been found in TT or PFS, it would be more advisable to use BFIR scheme due to its better results in OS and toxicity profile.PMID:34664108 | DOI:10.1007/s00228-021-03235-5
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Source Type: research